

Folotyn[®] (pralatrexate) – First-time authorized brand alternative

- On November 17, 2022, Fresenius launched an authorized brand alternative (ABA) of Acrotech Biopharma's [Folotyn \(pralatrexate\)](#) injection.
- Folotyn is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.